Article
Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib.
Systems biology - 1 Nov 2006
Hendriks B S, Griffiths G J, Benson R, Kenyon D, Lazzara M, Swinton J, Beck S, Hickinson M, Beusmans J M, Lauffenburger D, de Graaf D
Abstract excerpt
A majority of gefitinib (IRESSA)-responsive tumours in non-small cell lung cancer have been found to carry mutations in ErbB1. Previously, it has been observed that internalisation-deficient ErbB1 receptors are strong drivers of oncogenesis. Using a computational model of ErbB1 trafficking and signalling, it is found that a deficiency in ErbB1 internalisation is sufficient to explain the observed signalling...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.